CD8A and breast cancer: However, recent work including all subtypes of breast carcinomas concluded that CD3+, CD8+ and FOXP3+ lymphocyte densities did not add prognostic information over stromal TILs assessed on H&E in early intermediate/high-risk breast cancer treated with adjuvant chemotherapy (39).